Decreased immune function in cancer patients is well-characterized (I), and tumor cells have
developed a variety of mechanisms, to avoid anti-tumor immune responses (2–8). One …

Optimal host defense against pathogens requires cross-talk between the nervous and
immune systems. This paper reviews sympathetic-immune interaction, one major …

T-cell defects and premature thymic atrophy occur in cancer patients and tumor-bearing
animals. We demonstrate that exposure of mice to recombinant vascular endothelial growth …

Depressed immune responses have been observed frequently in cancer patients. In a
variety of human malignancies, the expression of interleukin-2 receptor α (IL-2Rα) on …

The curative ability of photodynamic therapy (PDT) is severely compromised if treated
tumors are growing in immunodeficient hosts. Reconstitution of severe combined …

The effect of chronic lymphocytic thyroiditis (CLT) on the behavior of papillary thyroid cancer
(PTC) remains unclear. In recent studies the presence of CLT in patients with PTC was …

Cytotoxic T lymphocytes (Tc) play a central role in cellular immunity against cancers. The
cytotoxic potential of freshly isolated tumor-infiltrating lymphocytes (TILs) is usually not …

Compiling significant advances from more than a decade of research, this text presents
breakthroughs in the prevention, treatment, and control of cancer-exploring the origin …

Monoclonal antibodies (mAbs) can be used therapeutically by binding to molecular targets
with high specificity. Therefore, they have excellent therapeutic applications in …

It has long been known that tumors become more clinically and biologically aggressive over
time. This has been termed 'tumor progression'and includes, among other properties …